Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Pancreatic Cancer Vaccine in Advanced Pancreatic Cancer
NCT03387098Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2017
- Primary completion
- Sep 2018
- Modality
- Vaccines & Immunotherapeutics, Adenoviral Vectors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK, ETBX-011, GI-4000, aldoxorubicin in pancreatic adenocarcinoma (PDAC), sponsored by ImmunityBio, Inc.. Started Dec 2017; status: terminated.
02
Drugs
nogapendekin alfa inbakicepthaNKETBX-011GI-4000aldoxorubicin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03387098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387098.